Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE VIVEX BIOMEDICAL, INC.
MARIETTA, Ga., Sept. 18, 2013 /PRNewswire/ -- VIVEX BIOMEDICAL, INC., a biomaterials manufacturer and developer, announced today that it has successfully completed its first round of private equity financing. The financing involved an over-subscribed offering of the Company's preferred stock, generating $7.6 million in start-up capital.
Tracy Anderson, President and CEO of Vivex, said, "We are grateful to our shareholders and investors. They have provided us capital to grow our rapidly expanding biosciences portfolio while allowing the executive team to focus on the strategic execution and day to day operations. We are excited about the future of Vivex."
Start-up capital will be used to refine current and develop new products, expand its team, and identify and pursue strategic partnerships and other opportunities. The company's patented flagship products, currently in development, include the MIAMI stem cell and mimetic pattern implants and other protected Intellectual Property. The company's core biomaterials include demineralized bone matrix, sponge, allograft, and calcium phosphate products backed by a proprietary cleansing process that sustains bioactivity.
About VIVEX BIOMEDICAL, INC.
Vivex commenced operations in 2013 following a spin-off of the biomaterials division of Amendia, Inc., a Marietta, Georgia spinal implant manufacturer, and has since experienced rapid growth. In support of the biologics-oriented platform, Vivex is developing a strategic portfolio of revolutionary interactive implants that nurture and guide the body's regenerative responses for accelerated healing while minimizing recuperation. The company's soon to be released flagship products range from bioresonant mimetic implants that encourage and enhance response from the body, to a revolutionary undifferentiated adult stem cell line that retains the multi-lineage potential to repair virtually any tissue type.
Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the federal security laws. Forward-looking statements are only predictions and are not guarantees of performance. You should not place undue reliance on any forward-looking statements.
For more information, please visit the company's website at www.vivex.com or contact the company's General Counsel, Michael F. Rozmajzl, Esq., CPA., at 770.575.5221.
©2012 PR Newswire. All Rights Reserved.